Exelixis Inc Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Exelixis Inc (EXEL) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $54.90 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-10
- 2026-01-02: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $54.90M.
- 2025-01-03: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $61.50M.
- 2023-12-29: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $58.70M.
- 2022-12-30: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $55.40M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed |
|---|---|---|
| 2026-01-02 | $54.90M 10-K · filed 2026-02-10 | |
| 2025-01-03 | $61.50M 10-K · filed 2025-02-11 | |
| 2023-12-29 | $58.70M 10-K · filed 2024-02-06 | |
| 2022-12-30 | $55.40M 10-K · filed 2023-02-07 | |
| 2021-12-31 | $52.60M 10-K · filed 2022-02-18 | |
| 2021-01-01 | $50.10M 10-K · filed 2021-02-11 | |
| 2020-01-03 | $48.10M 10-K · filed 2020-02-25 | |
| 2018-12-28 | $46.00M 10-K · filed 2019-02-22 | |
| 2014-12-31 | $100.00K 10-K · filed 2015-03-02 | |
| 2013-12-31 | $100.00K 10-K · filed 2016-02-29 | |
| 2012-12-31 | $100.00K 10-K · filed 2014-02-20 | |
| 2011-12-31 | $100.00K 10-K · filed 2014-02-20 | $126.00K 10-K · filed 2012-02-22 |
| 2010-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |